Publishing date: 1st September 2022
In this video module Quentin Anstee and Manal Abdelmalek will outline the common biomarkers for NASH, and discuss the current and future therapeutic landscape for the disease.
When you have completed this activity you will be asked to fill in a short evaluation survey. Your feedback helps us to give you the best learning experience.
In support of improving patient care, this activity is accredited by North American Center for Continuing Medical Education (NACCME) for 0.25 AMA PRA Category 1 Credit(s)™. Should you wish to claim credits for this activity, please select “yes” in the question below and download your certificate. Should you simply wish to provide us with valuable feedback, please select “no” in the question below and submit your feedback.
Login or create a free account to get started
Login
Register
Learning objectives
Following completion of this activity, you will be able to:
- Understand and implement the current clinical practice guidelines
- Identify patients at risk for advanced fibrosis
- Apply available non-invasive tools for the diagnosis of patients with NASH
- Review emergent therapies for the treatment of NASH
Faculty
Quentin Anstee
Professor of Experimental Hepatology, Newcastle University, UK
Honorary Consultant Hepatologist in the Liver Unit, the Newcastle upon Tyne Hospitals NHS, Foundation Trust, UK
Professor Quentin M. Anstee is the Chair of Experimental Hepatology and the Deputy-Dean of Research & Innovation in the Faculty of Medical Sciences, Newcastle University, UK. A practicing clinician, he is also an Honorary Consultant Hepatologist in the Liver Transplant Unit at Newcastle’s Freeman Hospital, where he leads one of the largest Non-Alcoholic Fatty Liver Disease (NAFLD) clinical services in the UK. He trained in medicine at University College London where he was awarded a First Class Honours degree and won First Prize in Medicine in the final MB BS examination.
Prof Anstee’s translational research has made major contributions across the pathophysiology, natural history, diagnosis and treatment of NAFLD. His work has provided key insights into temporal changes in steatohepatitis during disease evolution, identified genetic and epigenetic modifiers of liver disease progression and hepatocellular carcinoma risk, and has substantially advanced the field of biomarker development in liver disease. He coordinates two major international research consortia that are studying NAFLD pathogenesis and developing/validating accurate biomarkers to assist the diagnosis, risk-stratification and monitoring of patients with NAFLD: ‘EPoS’ Elucidating Pathways of Steatohepatitis (EU H2020 funded €6 million, 2015-2019) and ‘LITMUS’ Liver Investigation: Testing Marker Utility in Steatohepatitis (EU IMI2 funded €47.3 million, 2017-2022). He has established a pan-European NAFLD Registry and is the chief investigator of multiple ongoing clinical trials assessing new medical therapies for NAFLD. He is an Associate Editor of the Journal of Hepatology.
Disclosures
Coordinator of the EU IMI-2 LITMUS consortium, which is funded by the EU Horizon 2020 programme and EFPIA. This multi-stakeholder consortium includes industry partners.
Grants – Allergan/Tobira, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Glympse Bio, Intercept, Novartis Pharma AG, Pfizer Ltd.
Consulting – 89Bio, Abbvie/Allergan, Akero, Altimentiv, Altimmune, AstraZeneca, Axcella, Blade, BMS, BNN Cardio, Boehringer Ingelheim, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Company Ltd., Galmed, Genentech, Genfit SA, Gilead, Grunthal, HistoIndex, Indalo, Intercept Pharma Europe Ltd., Inventiva, IQVIA, Janssen, Johnson & Johnson, Madrigal, MedImmune, Medpace, Merck, Metacrine, NGMBio, North Sea Therapeutics, Novartis, Novo Nordisk A/S, PathAI, Pfizer Ltd., Poxel, ProSciento, Raptor Pharma, Roche, Servier, Shionogi, Terns, The Medicines Company, Viking Therapeutics.
Speaker – Abbott Laboratories, Allergan/Tobira, BMS, Clinical Care Options, Falk, Fishawack, Genfit SA, Gilead, Integritas Communications, Kenes, Medscape.
Royalties – Elsevier Ltd
Manal Adbelmalek
Professor of Medicine, Mayo Clinic, USA
Manal F. Abdelmalek, MD, MPH, FAASLD is tenured Professor of Medicine in the Division of Gastroenterology and Hepatology and Director of the Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Research Program at Duke University. Since first reporting on nonalcoholic steatohepatitis (NASH) as a cause of cryptogenic cirrhosis nearly 25 years ago, her clinical and research area of interest has focused on NAFLD / NASH, associated risk factors for disease acquisition and progression and the discovery of novel approaches to treatment. She has expertise in clinical-translational research, the design and conduct of clinical trials, including investigator-initiated, industry sponsored and NIH-funded clinical studies evaluating new therapies and biomarkers for NAFLD and NASH. She collaborates extensively to translate new compounds to first-in-man clinical studies and translate clinic-to-bench and bench-to-clinic research to define pathogenic mechanisms underlying NAFLD acquisition and progression. She is a key opinion leader in the field of NASH therapeutics, a member of the Liver Forum, and advisor/ consultant to many industries, FDA, and biomarker development companies in the area of diagnostics and therapeutics for NASH. She is the lead Principal Investigator on several multicenter global studies, a member of the AASLD Global Outreach and Engagement Committee and past member of the AASLD Clinical Research Committee. As a teacher and educator, she has mentored clinical residents, fellows, faculty at rank of Assistant / Associate Professor from Duke University as well as other institutions in the study and research of liver disease. Dr. Abdelmalek is a Fellow of American College of Physicians, American College of Gastroenterology and American Association for the Study of Liver Disease. She is a standing member of NASH Clinical Research Network (NASH CRN) for the past 15 years. Dr. Abdelmalek has published more than 200 manuscripts and currently serves on the Editorial Board of HEPATOLOGY, the official journal of the AASLD.
Disclosures
Grants / Honoraria – Intercept, Madrigal, Hanmi, Viking, NovoNordisk, NGM Bio, Allergan, Galmed, Novartis, Durect, Poxel, Progenity, Target Pharma, Inventiva, Enanta, Enyo, Celgene, Genentech, Boehringer-Ingelheim
Accreditation
In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.
NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NACCME designates AMA PRA Category 1 Credit™ for the following activities:
- Completion of 15-minute patient case study: 0.25 AMA PRA Category 1 Credit™
Expiration date: 28th July 2023 - Completion of 15-minute eLearning module: 0.25 AMA PRA Category 1 Credit™
Expiration date: 28th July 2023 - Completion of 20-minute video module: 0.25 AMA PRA Category 1 Credit™
Expiration date: 1st September 2023 - Completion of all components listed above and the opening/closing videos: 1.0 AMA PRA Category 1 Credit™
How to claim your credits
To claim your credits for participating in the accredited activities, you will need to complete the activity then fill out the short evaluation form at the end of each module.
Planning Committee
In addition to the expert faculty, NACCME and Springer Healthcare IME planners and staff include Kristin Kolack, Rachel Goddard, James Hutton, and Alba Ruzafa. The Planning Committee have no financial relationships to disclose.
Funding
This activity is supported by an educational grant from NOVO NORDISK A/S.
